Meeting
2020 Genitourinary Cancers Symposium
Edmonton Prostate Interdisciplinary Cancer Clinic (EPICC): Real-world efficacy outcomes of a multidisciplinary clinic for metastatic castration-resistant prostate cancer.
Authors
Graeme Follett
University of Alberta, Edmonton, AB, Canada
Graeme Follett , Derek Tilley , Naveen S. Basappa , Brita Lavender Danielson , Michael Chetner , Michael Paul Kolinsky , Scott A. North , Sarah Rayner-Myers , Gerry Todd , Adrian S. Fairey
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 36)
Abstract #
36
Poster Bd #
B2
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Efficacy of cabazitaxel (CABA) rechallenge in heavily-treated patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Constance Thibault
First Author: Elena Castro
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world treatment (Tx) sequences and time to discontinuation (rwTTD) in the first-line (1L) metastatic castration-resistant prostate cancer (mCRPC) setting.
First Author: Emily Nash Smyth
Poster
2023 ASCO Annual Meeting
Concurrent chemo-hormonal therapy of enzalutamide (ENZ) and cabazitaxel (CAB) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final analysis of objective response rate (ORR), radiographic progression-free survival (rPFS), and overall survival (OS).
First Author: Alexandra Sokolova